A phase 2b, randomised, double-blind, active controlled, multi centre study to evaluate the efficacy, safety and tolerability of oral AZD9977 and dapagliflozin treatment in patients with heart failure
11 May 2024 (08:00 - 20:00)
Organised by: 
About the speaker
Duke-NUS Graduate Medical School Singapore, Singapore (Singapore)
9 More presentations in this session
Doctor E. Meekers (Genk, BE)
Access the full session
The Event
Heart Failure 2024
11 May - 14 May 2024
You may be interested in
Congress Presentation
